Q1 2025 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2025-05-15 · accession 0001012975-25-000245
$206.2M
Reported value
9
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 07373V105 | BEAM | BEAM THERAPEUTICS INC. | $88.7M | 43.0% | 4,540,132 | Common | NONE |
| 578784100 | MAZE | MAZE THERAPEUTICS, INC. | $45.4M | 22.0% | 4,120,053 | Common | NONE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS, INC. | $37.5M | 18.2% | 3,728,738 | Common | NONE |
| 29479A108 | ERAS | ERASCA, INC. | $15.1M | 7.34% | 11,055,554 | Common | NONE |
| 92539P101 | — | VERVE THERAPEUTICS, INC. | $9.1M | 4.42% | 2,008,809 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO, INC. | $8.8M | 4.26% | 8,055,916 | Common | NONE |
| 91381U200 | UNBX | UNITY BIOTECHNOLOGY, INC. | $1.0M | 0.51% | 1,004,817 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC. | $532,000 | 0.26% | 320,482 | Common | NONE |
| 71902K303 | — | CERO THERAPEUTICS HOLDINGS, INC. | $16,134 | 0.01% | 22,102 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.